Income statement
INR
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.9B | 1.9B | 1.6B | 1.1B | 893M |
| Gross Profit | 24M | 52M | 57M | 33M | 13M |
| Operating Income | 20M | 48M | 55M | 24M | 11M |
| EBITDA | 11M | 40M | 45M | 25M | 6M |
| Net Income | 20M | 44M | 44M | 16M | 2M |
| EPS (Diluted) | — | — | — | — | — |
Financial Services
Live Price
Offline$63.22
-0.66% today
1Y Change
+5.86%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
BlackRock Health Sciences Opportunities Portfolio Service Shares (SHISX) is a fund with a market cap of $567.49B and listed on NASDAQ. The fund last traded around $63.22 and up 5.9% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include a dividend yield of 11.2%. Valuation already assumes a fairly strong business story at P/E 3578.2 and price/sales 303.7. Stock Foundry combines SHISX price history, analyst forecasts, news, related Financial Services peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SHISX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SHISX Max Drawdown
-13.47%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SHISX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$892.6M
-22.3% YoY
FY Net Income
$2.3M
-85.2% YoY
Free Cash Flow
$28.6M
+3503.1% YoY
Revenue Growth
-3.1%
EPS Growth
-60.5%
Gross Margin
1.3%
Net Margin
1.1%
Income statement
INR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.9B | 1.9B | 1.6B | 1.1B | 893M |
| Gross Profit | 24M | 52M | 57M | 33M | 13M |
| Operating Income | 20M | 48M | 55M | 24M | 11M |
| EBITDA | 11M | 40M | 45M | 25M | 6M |
| Net Income | 20M | 44M | 44M | 16M | 2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
INR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 35M | 54M | 79M | 31M | 30M |
| Total Assets | 684M | 549M | 337M | 243M | 202M |
| Total Liabilities | 214M | 212M | 178M | 178M | 156M |
| Shareholder Equity | 470M | 337M | 128M | 64M | 46M |
| Total Debt | 13M | 0 | 31M | 34M | 31M |
| Net Debt | -22M | -54M | -48M | 4M | 2M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
29M
+903.8% YoY
Capital Expenditures
109K
+94.7% YoY
Free Cash Flow
29M
+3503.1% YoY
Key ratios
Gross Margin
1.3%
Operating Margin
1.1%
Net Margin
1.1%
ROE
5.0%
Debt / Equity
0.03x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.